Font: Financial Modeling Prep • Jan 08, 2026
Acuity Brands (NYSE: AYI) reported first-quarter fiscal 2026 adjusted earnings that came in above analyst estimates, driven by solid revenue growth and margin improvement, though shares dropped more than 12% intraday on Thursday.
The company posted adjusted earnings of $4.69 per share for the quarter ended November 30, 2025, exceeding the consensus estimate of $4.58. Revenue rose 20.2% year over year to $1.14 billion, matching analyst expectations.
Revenue growth was led by the Acuity Intelligent Spaces segment, where sales surged 250.2% to $257.4 million. Meanwhile, the Acuity Brands Lighting segment recorded a more modest 1% increase in sales to $895.1 million.
Adjusted operating profit increased 23.7% to $196.3 million, while adjusted operating margin expanded 50 basis points to 17.2%. The company generated $140.8 million in operating cash flow during the quarter and repurchased approximately 77,000 shares for about $28 million.
Acuity also reduced debt, repaying $100 million of term-loan borrowings during the quarter. Segment profitability improved as well, with adjusted operating margin in the AIS business rising 100 basis points to 22.0%, while the lighting segment’s margin increased 60 basis points to 17.9%.
|
GV§>
Visionary Holdings Inc.
|
$0.44
116.78%
|
|
LNKS§>
Linkers Industries Limited
|
$0.01
-35.16%
|
|
AIXI§>
Xiao-I Corporation
|
$0.13
33.10%
|
|
SKYQ§>
Sky Quarry Inc.
|
$5.10
101.58%
|
|
NVDA§>
NVIDIA Corporation
|
$177.39
0.93%
|
|
BITO§>
ProShares - Bitcoin ETF
|
$9.21
-1.60%
|
|
COCP§>
Cocrystal Pharma, Inc.
|
$1.51
48.04%
|
|
TSLL§>
Direxion Daily TSLA Bull 2X ETF
|
$11.37
-10.96%
|
|
SPDN§>
Direxion Daily S&P 500 Bear 1X ETF
|
$9.87
0.10%
|
|
BDRX§>
Biodexa Pharmaceuticals Plc
|
$0.87
42.23%
|